Current Assets
Allowance for Doubtful Accounts Receivable (Current)
Moderna Allowance for Doubtful Accounts Receivable (Current) increased by 100.0% to $6.00M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryRisk
SignalLower is better
VolatilityStable
First reportedQ4 2024
Last reportedQ1 2026May 1, 2026
How to read this metric
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
Detailed definition
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Peer comparison
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
Metric ID:
allowance_for_doubtful_accounts_receivable_currentHistorical Data
5 periods
| Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $0.00 | $12.00M | $3.00M | $3.00M | $6.00M |
| QoQ Change | — | — | -75.0% | +0.0% | +100.0% |
Range$0.00 – $12.00M
Current Streak2 quarters growth
Allowance for Doubtful Accounts Receivable (Current) at Other Companies
Frequently Asked Questions
- What is Moderna's allowance for doubtful accounts receivable (current)?
- Moderna (MRNA) reported allowance for doubtful accounts receivable (current) of $6.00M in Q1 2026.
- What does allowance for doubtful accounts receivable (current) mean?
- The estimated portion of customer invoices that the company expects will never be paid.